SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sionna Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.01+0.12 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $181.05M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.66 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.60 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 2, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | $-0.46 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | – | $-3.38 | – |
Press releases
Announcements Sionna Therapeutics filed with the SEC
Sionna Therapeutics Announces Plans to Advance SION-451 +
Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides
Other events · EX-99.1 to Form 8-K
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719
Regulation FD disclosure · EX-99.1 to Form 8-K
Sionna Therapeutics Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K